An Analytical Study on PCOD with Reference to Clinical and Biochemical Parameters

  • Divya Mittal Assistant Professor, Department of Obstetrics & Gynaecology, Rohilkhand Medical College and Hospital, Bareilly.
  • Alka Agarwal Assistant Professor, Department of Obstetrics & Gynaecology, Rohilkhand Medical College and Hospital, Bareilly.
Keywords: PCOD, Clinical parameters


Background: The association of PCOS to menstrual cycle abnormalities has been already established. Menstrual irregularities appear to precede the presence of PCOS. It is evident that there is a close relation between the degree of cycle irregularities and the grade of endocrine and metabolic disorders among the PCOS women.

Methods: In this study 100 cases were included. This study was conducted in the Department of Gynecology. The duration of study was over a period of two year.

Results: Among 100 cases, 66 cases had menstrual irregularity, 22 cases had Hyperandrogenism & infertility seen 12 cases.

Conclusions: This study concludes that; menstrual irregularities are most presenting symptom in PCOS. TVS is the most the important diagnostic tool. Obesity and overweight is a most important modifiable risk factor which will prevent this disorder.


Download data is not yet available.


1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer E, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 2004, vol. 89 (pg. 2745-2749) 10.1210/jc.2003-032046
2. Palmert MR, Gordon CM, Kartashov A , Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome, J Clin Endocrinol Metab, 2002, vol. 87 (pg. 1017-1023) 10.1210/jc.87.3.1017
3. Bouzas IC, Cader SA, Leao L, Kuschnir MC, Braga C. Menstrual cycle alterations during adolescence: early expression of metabolic syndrome and polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2014;27:335–41. [PubMed] [Google Scholar]
4. Pinola P, Lashen H, Bloigu A, Puukka K, Ulmanen M, Ruokonen A, et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod. 2012;27:3279–86. [PubMed] [Google Scholar]
5. Strowitzki T, Capp E, von Eye Corleta H. The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients. Eur J Obstet Gynecol Reprod Biol. 2010;149:178–81. [PubMed] [Google Scholar]
6. Xu XH, Tan YC, Shi YH, Wang B, Ju XQ, Zheng QM, et al. Different types of menstrual cycle and their significance in Chinese women diagnosed with polycystic ovary syndrome according to the Rotterdam consensus criteria] Zhonghua Yi Xue Za Zhi. 2009;89:2604–6. [PubMed] [Google Scholar]
7. Xu X, Shi Y, Cui Y, Ma J, Che L, Chen ZJ. Endocrine and metabolic characteristics of polycystic ovary syndrome in Chinese women with different phenotypes. Clin Endocrinol (Oxf) 2012;76:425–30. [PubMed] [Google Scholar]
8. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008;93:1276–84. [PMC free article] [PubMed] [Google Scholar] Retracted
9. Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, et al. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones (Athens) 2015;14:431–7. [PubMed] [Google Scholar]
10. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2011;24:161–5.
11. R. A. Lobo and E. Carmina, “Importance of Diagnosing PCOS,” Annuals of Internal Medicine, Vol. 32, No. 2000, pp. 989-993.
12. E. A. Nager and PA-C and MMS, “Prompt Treatment Is Necessary to Control and Prevent Further Progression of Pcos Related Insulin Resistance, Dyslipidemia, Type 2 Diabetes, Cardiovascular Disease and Cancer,” Search Archives, Vol. 14, No. 1, 2006, p. 49.
13. D. A. Ehrmann, “Polycystic Ovary Syndrome,” The New England Journal of Medicine, Vol. 352, No. 2005, pp. 12223-12236. doi:10.1056/NEJMra041536
14. Polycystic Ovary Syndrome Writing Committee, “AACE Position Statement on Metabolic & CVS Consequences of Polycystic Ovary Syndrome,” Endocrine Practice, Vol. 11, No. 2, 2005, p. 125.
15. Balen A, Conway G, Klatas G et al. Polycystics ovary syndrome: the spectrum of the disorder in 1741 patients. Human Reproduction 1995; 10: 2107 - 2111.
16. Turhan NO, Seckin NC, Aybar F and Inegol I (2003) Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet 81,163–168.
17. Gülekli B, Turhan NO, Senoz S, Kukner S, Oral H. Gükmen O. Endoclogical, ultrasonographic and clinical findings in adolescent and adult polycystics ovary patients : a comparative study. Gynecol Endocrinol. 1993 Dec; 7(4): 273 -7
18. Aarti Sharma and William Atiomo. Recent development in polycystic ovary syndrome. Current Obstetrics & Gynaecology (2003) 13, 281 – 286.
How to Cite
Mittal D, Agarwal A. An Analytical Study on PCOD with Reference to Clinical and Biochemical Parameters. Int Arch BioMed Clin Res [Internet]. 2020Mar.30 [cited 2020May28];6(1):OG4-OG6. Available from:
ORIGINAL ARTICLES ~ Obstetrics & Gynaecology